SAN DIEGO, Dec. 30, 2020 /PRNewswire/ -- Biocept,
Inc. (Nasdaq: BIOC), a leading commercial provider of
molecular diagnostic assays, products and services designed to
provide physicians with clinically actionable information to
improve patient outcomes, announces that it has entered into
laboratory services agreements with independent physician
associations (IPAs) providing physicians and patients in-network
access to Biocept's full array of Target Selector™ liquid biopsy
oncology assays and services. Both IPAs are headquartered in
San Diego and combined serve more
than 70,000 covered lives in the Southern
California region.
"We see a role for our Target Selector™ assays and services in
value based delivery health plans such as IPAs with goals to
deliver cost-efficient and high-quality care," said Michael Nall, Biocept's President and CEO. "Our
Target Selector™ provides evidence-based, clinically actionable
results that allow physicians the ability to choose individual
biomarker tests or larger liquid biopsy panels to provide the best
approach for each patient. Contracting with value-based
providers is a priority for Biocept and we expect to enter into
additional services agreements in the future."
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic
options. Additionally, Biocept is offering nationwide COVID-19
polymerase chain reaction (PCR) testing to support public health
efforts during this unprecedented pandemic. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements regarding our expectation of entering
into additional services agreements in the future and the ability
of our assays to improve the outcomes of patients diagnosed with
cancer, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risks and uncertainties, including the risk
that our products and services may not perform as expected and the
risk that we will not be able to enter into additional services
agreements. These and other risks are described in greater detail
under the "Risk Factors" heading of our Quarterly Report on Form
10-Q for the quarter ended September 30, 2020. The effects of
such risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC,
which can be accessed over the Internet at
the SEC's website located at www.sec.gov.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-enters-into-laboratory-services-agreements-with-two-southern-california-regional-independent-physician-associations-301199215.html
SOURCE Biocept, Inc.